Design and rationale of MASTERKEY-115 phase II trial of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in patients with advanced melanoma who progressed on prior anti-programmed cell death-1 (anti-PD-1) therapy.

Authors

Jason Alan Chesney

James Graham Brown Cancer Center, University of Louisville, Louisville, KY

Jason Alan Chesney , Mohammed M. Milhem , Marya F. Chaney , Priya Gokani , Wendy Snyder , Caroline Robert

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti–PD-1 therapy: MASTERKEY-115.

First Author: Brian Gastman

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A phase II study of anti-PD1 monoclonal antibody (Nivolumab) administered in combination with anti-LAG3 monoclonal antibody (Relatlimab) in patients with metastatic melanoma naive to prior immunotherapy in the metastatic setting.

First Author: Anjali Rohatgi

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy.

First Author: Antoni Ribas

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).

First Author: F. Stephen Hodi